Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. - Wikidata - wikimedia - TriplyDB

Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.

Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33785710

about

Histone Deacetylases and Their Regulatory MicroRNAs in Hepatocarcinogenesis Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma Epigenetics in liver disease: from biology to therapeutics Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation.A critical role for ZDHHC2 in metastasis and recurrence in human hepatocellular carcinoma.Epigenetic upregulation of Bak by ZBP-89 inhibits the growth of hepatocellular carcinoma.Nanosecond pulsed electric field inhibits cancer growth followed by alteration in expressions of NF-κB and Wnt/β-catenin signaling molecules Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma ZBP-89 reduces histone deacetylase 3 by degrading IkappaB in the presence of Pin1 Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma.Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib Droxinostat, a Histone Deacetylase Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cell Lines via Activation of the Mitochondrial Pathway and Downregulation of FLIP.AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.Prognostic indicators for tumor recurrence after liver transplantation in hepatocellular carcinoma and related molecular targeted therapy.HDAC inhibitor-based therapies: can we interpret the code?Emerging signaling pathways in hepatocellular carcinoma.Genetic and epigenetic alterations in hepatitis B virus-associated hepatocellular carcinoma.Recent advance of the hepatitis B virus inhibitors: a medicinal chemistry overview.The role of REST and HDAC2 in epigenetic dysregulation of Nav1.5 and nNav1.5 expression in breast cancer.Histone deacetylases function as a novel potential therapeutic target for cancer.The up-regulation of histone deacetylase 8 promotes proliferation and inhibits apoptosis in hepatocellular carcinoma.Epigenetic targets in hepatocellular carcinoma cells: identification of chaperone protein complexes with histone deacetylases.A novel treatment strategy in hepatocellular carcinoma by down-regulation of histone deacetylase 1 expression using a shRNA lentiviral system.The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.Histone deacetylase 3 overexpression in human cholangiocarcinoma and promotion of cell growth via apoptosis inhibition Alterations of epigenetics and microRNA in hepatocellular carcinoma.Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.Epigenetic reprogramming in liver fibrosis and cancer.Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells.Resminostat induces changes in epithelial plasticity of hepatocellular carcinoma cells and sensitizes them to sorafenib-induced apoptosis.Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.Hepatitis B Virus-Associated Hepatocellular Carcinoma and Hepatic Cancer Stem Cells.Highly expressed histone deacetylase 5 promotes the growth of hepatocellular carcinoma cells by inhibiting the TAp63-maspin pathway.Histone deacetylase 3 promotes liver regeneration and liver cancer cells proliferation through signal transducer and activator of transcription 3 signaling pathway.

P2860

Q26783620-ABA7DBB4-1DF6-4914-867C-BFC4F5E4913E Q26797616-53BE1BAF-49AC-49E6-B76F-A7E1CA54F7AB Q27023524-9BB7DB6C-D355-45CF-B9B1-7B2E81419082 Q28079271-9065F921-8C03-45F3-8A60-3857288F2E65 Q31037974-BF6DD75E-0FDE-4973-BD7D-25978A130A3D Q33796757-B6099E68-F135-41FC-B87E-5567D406541A Q34159310-DAF4D20F-27CD-4606-86D5-522BA2D2A8BE Q34999115-15141A99-D423-47C1-B865-1513EF686DE2 Q35000109-CFAFAC88-441A-438B-B0E6-6D76CD35429A Q35030172-058EE5F3-0565-4616-B990-A0418B588275 Q35632953-886EB484-6E20-4443-B943-1524A5AF7987 Q35968727-98403CB8-61DB-4F21-9B0D-2D2E2AB9DD09 Q36707143-81EFC3C0-1286-4FA5-8D87-23E316427A99 Q37222637-5FE53864-05F2-4B79-861A-7A76A0D3C6E9 Q37972812-D0A707DF-527A-4D9C-82C0-844BEE2E115E Q38058971-01F9FADD-684A-489E-A8C0-A320B94ACAB6 Q38155507-F96F5534-8F6E-4326-B6F0-1F79922F2382 Q38415638-86E0AD6D-8226-4DA9-B1A5-F2C405F7E466 Q38447283-C71B6000-50B5-4042-8026-3B06F2814D5B Q38695555-7A47D5DD-7D04-421F-BCE9-0885C41AB2C0 Q38908331-A948B9F6-9E20-4829-ACE3-D18A08627C29 Q39090052-4BB1043F-D6C3-4588-8F41-29A839D9DAA1 Q39092838-688D8678-6288-42AF-8CCE-0E2B1C9D97BD Q40832236-42EFF753-EAD9-4473-998E-85B4924129B7 Q40971366-69F7B1A1-9E5F-43EC-86C8-18F7CFBCEA3A Q41083899-ADA210A8-C800-47E5-B879-861C04CB8D4F Q45925779-175CBAC8-33C4-4D64-AE45-C63CBF4E436B Q47096044-698416A5-1521-4530-A2D2-DC4A82D97C4B Q47157566-48C64F0B-25B3-45D3-A902-815B0CDD812E Q48261101-C9DAA289-BD34-44A6-8E79-966C1AE4903B Q49334697-3CAE9A89-CA29-40C5-A03C-AB4BA149D2DA Q51374040-2F2395E8-8921-4AA6-86B2-32F910FBE6D6 Q52369573-2AB8A33B-EE9A-4CF8-8D01-CB7D979C794E Q52595049-AB5178B3-9C7F-4782-B88B-D058ABB4A97A Q52689599-0556C6D0-BCD5-4239-9007-E7569210D7D1

P2860

Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma.

http://www.wikidata.org/entity/Q33785710

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Identification of histone deac ...... ated hepatocellular carcinoma.

@ast

Identification of histone deac ...... ated hepatocellular carcinoma.

@en

type

label

Identification of histone deac ...... ated hepatocellular carcinoma.

@ast

Identification of histone deac ...... ated hepatocellular carcinoma.

@en

prefLabel

Identification of histone deac ...... ated hepatocellular carcinoma.

@ast

Identification of histone deac ...... ated hepatocellular carcinoma.

@en

P1433

Q33785710-69214098-48F4-4A9D-A8E9-5F7A88839DAF

P1476

Q33785710-500A16C7-C3FB-4F56-8897-3B28B03F8C89

P2093

Q33785710-4D20A3A4-85AF-47D9-A146-79189C75EF15

Q33785710-5531FE68-3607-4795-A19D-1123F933EF85

Q33785710-7D1AF4AC-EFC3-4810-B844-3E5A7AD8FE0C

Q33785710-8B837655-E3C6-4423-A6B6-8DBEE674FEDE

Q33785710-9E5B905E-3452-41B3-99A9-00055761DAC5

Q33785710-DEDE8DFB-9478-4B3B-B482-AFDCABFCC4A2

Q33785710-F0F97326-D66C-459E-8D29-10A7C3CF676F

P2860

Q33785710-01323D44-BF8D-41C7-94B4-C3D7AE0513CD

Q33785710-1B8EBC1D-C180-424C-989A-2BBF263E431D

Q33785710-1D8DC25F-557E-4EC7-88C8-4B5112707ED9

Q33785710-2A120D30-9C2D-4B00-B45F-54A162B19E92

Q33785710-2A297887-CD2D-42D4-ACA7-8237906FA9C0

Q33785710-2DDFF7A5-F98D-4D5E-B52F-CE43CDF685D8

Q33785710-415F4766-0094-4E26-8809-825A72B5917E

Q33785710-443B9186-404F-43F9-AD74-B1048996A006

Q33785710-480A3FCA-E551-4A34-8BD3-F42FB75664E0

Q33785710-4C13D989-F1A1-4623-A3A6-2C41B8EE5573

P304

Q33785710-873DA062-5ADC-443A-8A7B-AD27705E23E5

P31

Q33785710-647D7719-DA7A-40F9-B93E-A8BD4FFE35DA

P356

Q33785710-DE02C3C7-733B-4BC4-B011-A6187FB78CCB

P407

Q33785710-ED0A27C5-E722-49F5-A370-DBFDD2793D6A

P433

Q33785710-279BA3BE-E899-4529-BA70-FEE00A500B36

P478

Q33785710-3B68381C-6A30-4667-8FEF-D477ED69E689

P50

Q33785710-12862E9A-568C-4F3A-8A43-CF104F771C86

P577

Q33785710-2FCCC534-C5D7-4E99-98E1-14770292E0B4

P5875

Q33785710-74AE644C-CF4A-4DE5-B23E-DFAEBDFA6AFA

P698

Q33785710-FC919741-A4DB-4580-BEC0-47403359BD5C

P921

Q33785710-1D10CB89-5E7E-4018-B127-9BD16D755BE5

Q33785710-4C9F2CF1-ECC2-415D-B354-EF393EE8421D

P932

Q33785710-23E6EC26-C52F-4EFD-A5D7-BD7BA5157F3B

P356

JOURNAL.PONE.0014460

P1433

P1476

Identification of histone deac ...... ated hepatocellular carcinoma.

@en

P2093

Feng Zhang

http://www.w3.org/2001/XMLSchema#string

Hai-Yang Xie

http://www.w3.org/2001/XMLSchema#string

Jian Wu

http://www.w3.org/2001/XMLSchema#string

Li-Ming Wu

http://www.w3.org/2001/XMLSchema#string

Lin Zhou

http://www.w3.org/2001/XMLSchema#string

Xiao-Wen Feng

http://www.w3.org/2001/XMLSchema#string

Zhe Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

Epidemiology of primary liver cancer.

Primary prevention of hepatocellular carcinoma in developing countries.

Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

Predictive value of expression and promoter hypermethylation of XAF1 in hepatitis B virus-associated hepatocellular carcinoma treated with transplantation.

Histone acetylation and gastrointestinal carcinogenesis.

Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies.

Epigenetic therapy of cancer: past, present and future.

P304

e14460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0014460

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49729307

http://www.w3.org/2001/XMLSchema#string

P698

21206745

http://www.w3.org/2001/XMLSchema#string

P921

liver transplantation

P932

3012077

http://www.w3.org/2001/XMLSchema#string